P. B. Chapman, A. Hauschild, and C. Robert, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, NEJM, vol.364, issue.26, pp.2507-2516, 2011.

K. T. Flaherty, I. Puzanov, and K. B. Kim, Inhibition of mutated, activated BRAF in metastatic melanoma, NEJM, vol.363, issue.9, pp.809-819, 2010.

G. A. Mcarthur, P. B. Chapman, and C. Robert, Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, Lancet Oncol, vol.15, issue.3, pp.323-355, 2014.

A. Hauschild, J. J. Grob, and L. V. Demidov, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, vol.380, issue.9839, pp.358-365, 2012.

G. V. Long, A. Hauschild, and M. Santinami, Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma, NEJM, vol.377, pp.1813-1836, 2017.

H. Davies, G. R. Bignell, and C. Cox, Mutations of the BRAF gene in human cancer, Nature, vol.417, issue.6892, pp.949-54, 2002.

S. Laquerre, M. Arnone, and K. Moss, A selective RAF kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RAFV600E mutation, Abstract B88, vol.8, 2009.

G. Bollag, P. Hirth, and J. Tsai, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, vol.467, issue.7315, pp.596-599, 2010.

G. V. Long, D. Stroyakovskiy, and H. Gogas, Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, NEJM, vol.371, issue.20, pp.1877-88, 2014.

J. Larkin, P. A. Ascierto, and B. Dréno, Combined vemurafenib and cobimetinib in BRAFmutated melanoma, NEJM, vol.371, issue.20, pp.1867-76, 2014.

M. J. Garnett, S. Rana, and H. Paterson, Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization, Mol Cell, vol.20, issue.6, pp.963-972, 2005.

G. Zheng, L. H. Tseng, and G. Chen, Clinical detection and categorization of uncommon and concomitant mutations involving BRAF, BMC Cancer, vol.15, p.779, 2015.

J. S. Ross, K. Wang, and J. Chmielecki, The distribution of BRAF gene fusions in solid tumors and response to targeted therapy, Int J Cancer, vol.138, issue.4, pp.881-90, 2016.

K. E. Hutchinson, D. Lipson, and P. J. Stephens, BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition, Clin Cancer Res, vol.19, issue.24, pp.6696-702, 2013.

A. M. Menzies, I. Yeh, and T. Botton, Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion, Pigment Cell Melanoma Res, vol.28, issue.5, pp.607-617, 2015.

M. A. Ihle, J. Fassunke, and K. König, Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations, BMC Cancer, vol.14, p.13, 2014.

G. M. Frampton, A. Fichtenholtz, and G. A. Otto, Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing, Nat Biotechnol, vol.31, pp.1023-1054, 2013.

A. Drilon, L. Wang, and M. E. Arcila, Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in "driver-negative" lung adenocarcinomas, Clin Cancer Res, vol.21, pp.3631-3640, 2015.

A. B. Schrock, G. M. Frampton, and D. Herndon, Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing, Clin Cancer Res, vol.22, issue.13, pp.3281-3286, 2016.

D. Capper, A. S. Berghoff, and M. Magerle, Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases, Acta Neuropathol, vol.123, issue.2, pp.223-256, 2012.

G. V. Long, J. S. Wilmott, and D. Capper, Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma, Am J Surg Pathol, vol.37, issue.1, pp.61-66, 2013.

J. G. Reiter, . Makohon-mooreap, and J. M. Gerold, Minimal functional driver gene heterogeneity among untreated metastases, Science, vol.361, issue.6406, pp.1033-1040, 2018.

S. E. Bowyer, A. D. Rao, and M. Lyle, Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma, Melanoma Res, vol.24, issue.5, pp.504-512, 2014.

K. B. Dahlman, J. Xia, and K. Hutchinson, BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors, Cancer Discov, vol.2, issue.9, pp.791-798, 2012.

A. M. Menzies, I. Yeh, and T. Botton, Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion, Pigment Cell Melanoma Res, vol.28, issue.5, pp.607-617, 2015.

Z. R. Chalmers, C. F. Connelly, and D. Fabrizio, Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden, Genome Med, vol.9, issue.1, p.34, 2017.

D. B. Johnson, G. M. Frampton, and M. J. Rioth, Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade, Cancer Immunol Res, vol.4, issue.11, pp.959-967, 2016.

A. M. Goodman, S. Kato, and L. Bazhenova, Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers, Mol Cancer Ther, vol.16, issue.11, pp.2598-2608, 2017.